Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
A concise checklist to verify inputs, validate assumptions, and confirm your zero based budget remains aligned with priorities.
17,617 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
A timely look at Warren Buffett’s Coca-Cola investment and how Berkshire’s KO stake has powered decades of dividend g...
Barclays slashed Molson Coors' price target to $40, underscoring earnings headwinds as the brewer anticipates a tough...
Olaplex shares exploded after Henkel announced a cash buyout. This piece breaks down what happened, why it matters fo...
Amazon launches a $200 billion AI-focused capex plan for 2026, with Trainium and Anthropic in the mix. Here’s what in...
Investors are watching Criteo's early 2026 results to gauge the ad-tech pioneer's progress in privacy-friendly target...
A newly launched AI agent is set to overhaul how builders screen land and gauge deal risk, potentially speeding loans...
SVB Capital, the bank's roughly $10 billion venture arm, is being shopped as regulators unwind SVB assets. Buyers are...
A thorough look at Novanta's Q1 2026 results and what they signal for novanta (novt) 2026 earnings. We break down rev...
Artificial intelligence is reshaping how investors judge profitability. This article dives into three AI infrastructu...
Regulatory momentum around the CLARITY Act sparked a short-lived Bitcoin rally as markets anticipated a clearer U.S. ...
Intel faces a pivotal moment as Q1 losses mount and cash burn deepens. Analysts and investors debate buy, hold sell i...